4:45p.m. August 31, 2006
Prostate cancer is the second leading cause of cancer death in men in the U.S., but the good news is that survival rates are improving thanks in part to new clinical trials.
Clinical research nurse Maryann Heddon said, "All advancements in cancer care have been through clinical trials and that's the main reason we offer them.”
This trial, called Ascent-2, involves taking an investigational high dose calcitriol pill called DN 101.
Dr. Eric Anderson said, "The experimental drug, which is basically a vitamin they take orally once a week, has shown to help the men tolerate the chemotherapy better and the response rate and survival rate is better."
The Pearlman Comprehensive Cancer Center is the only medical center in south Georgia that's offering this type of research. Doctors here are very excited and are encouraging all eligible candidates to apply.
Dr. Anderson added, "What we're hoping to do is enroll men who need chemotherapy on this trial, not only to obtain data showing this will be a standard of care in the future, but also help their treatment currently."
The DN 101 drug will be provided to all qualified study participants at no cost.
Over 200,000 new cases of prostate cancer are diagnosed annually in the U.S. Patients or physicians interested in referrals can contact the Pearlman Cancer Center at 229-259-4616.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or email@example.com.